Interleukin-23p19 Inhibitors in Inflammatory Bowel Disease: From Current Insights to Future Directions - PubMed
5 hours ago
- #IL-23p19 inhibitors
- #inflammatory bowel disease
- #precision medicine
- Interleukin-23 (IL-23) is a key cytokine in inflammatory bowel disease (IBD) driving intestinal inflammation.
- Monoclonal antibodies targeting the p19 subunit of IL-23 (e.g., risankizumab, mirikizumab, guselkumab) have expanded IBD treatment options.
- Phase 3 trials in Crohn's disease (CD) and ulcerative colitis (UC) show high efficacy, leading to regulatory approvals.
- The SEQUENCE trial demonstrated risankizumab's superiority over ustekinumab in CD, highlighting the value of IL-23p19 blockade.
- IL-23p19 inhibitors offer favorable safety profiles and convenient subcutaneous administration.
- Key gaps remain in treatment positioning, comparative effectiveness, and long-term outcomes.
- Precision medicine approaches, including biomarkers, are crucial for optimizing IL-23p19 inhibitor use.
- Future research aims to integrate serological and multi-omics biomarkers for personalized treatment selection.
- IL-23p19 inhibitors exemplify the convergence of targeted immunotherapy and precision medicine in IBD management.